Taking into account the effectiveness of the current RA therapies against the main products of activated pro-inflammatory macrophages (TNFα, IL-1β, and IL-6) and the positive correlation between macrophage numbers and joint erosion (Hamilton and Tak, 2009), we can strongly identify macrophages as a crucial target for therapeutic intervention (Figure 1). Here, IL1B is linked to rheumatoid arthritis.